Voyager Therapeutics

VYGRNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$193.480 M

$3.14 +1.95%

Close of 22 Sept 2026

Revenue

$40.4M

#2799 by revenue

Earnings

-$119.7M

Loss-making

Shares outstanding

61,617,948

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#99Coherus OncologyCHRS$200.9M
#100Precision BiosciencesDTIL$198.5M
#101Voyager TherapeuticsVYGR$193.5M
#102Acumen PharmaceuticalsABOS$191.6M
#103Outlook TherapeuticsOTLK$169.5M

What if Voyager Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.2T

$490,668.23

Per share 156,264× higher

Bitcoin $1.74T

$28,265.39

Per share 9,002× higher

Nvidia $5.52T

$89,515.59

Per share 28,508× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Voyager Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.